SLC8A3: A Potential Drug Target and Biomarker for Chronic Pain Management

Target Name: SLC8A3

NCBI ID: G6547

SLC8A3

SLC8A3: A Potential Drug Target and Biomarker for Chronic Pain Management

Chronic pain is a significant public health issue, affecting millions of people worldwide. The World Health Organization (WHO) estimates that approximately 57% of the global population experiences chronic pain, with costs associated with such pain reaching as much as $63 billion annually. Chronic pain can be caused by various conditions, including neurological and psychiatric disorders, as well as accidental injuries or other factors. Management of chronic pain remains a challenge, and finding new and effective treatments is crucial.

Sodium/calcium exchanger 3 (ISOform C), also known as SLC8A3, has emerged as a promising drug target and biomarker for the management of chronic pain. SLC8A3 is a transmembrane protein that plays a crucial role in the regulation of sodium and calcium ions in the body. Its function is to maintain the proper balance of these ions in the cell, ensuring that cells are able to function properly and transmit signals.

SLC8A3 has been shown to be involved in various biological processes, including pain perception and management. Several studies have demonstrated that alterations in SLC8A3 levels or activity can contribute to the development and maintenance of chronic pain. Furthermore, inhibition of SLC8A3 has been shown to provide therapeutic benefits in pain management strategies, suggesting that it may be a valuable target for the development of new pain treatments.

Drug Target Potential

SLC8A3 is a potential drug target for several reasons. Firstly, its involvement in the regulation of ion balance makes it an attractive target for drugs that aim to alleviate pain by modulating ion channels or intracellular signaling pathways. Secondly, SLC8A3 is known to play a role in pain perception and neurotransmission, providing a potential explanation for its potential efficacy in pain treatments.

SLC8A3 has been shown to modulate pain-related ion channels, including the N-methyl-D-aspartate (NMDA) receptor, which is involved in pain perception and neurotransmission. Activation of the NMDA receptor can lead to increased pain sensitivity, while inhibition of its function has been shown to provide analgesic effects. Therefore, targeting SLC8A3 with drugs that specifically modulate NMDA receptor function could be a promising strategy for pain management.

Biomarker Potential

SLC8A3 has also been shown to serve as a potential biomarker for the assessment of chronic pain. Chronic pain is often associated with inflammation, which can be evaluated using various biomarkers. SLC8A3 has been shown to be involved in the regulation of inflammation and immune cell function, suggesting that its levels or activity may be relevant to the intensity of chronic pain.

Immunomodulation is a growing area of research, and SLC8A3 has been shown to play a role in this process. SLC8A3 has been shown to regulate the activity of immune cells, including T-cells, which are involved in the regulation of pain and inflammation. Therefore, targeting SLC8A3 with drugs that enhance or inhibit its immune cell function could be a promising strategy for the treatment of chronic pain.

Methodology

To investigate the potential drug target and biomarker properties of SLC8A3, several in vitro and in vivo studies have been conducted. In vitro studies have shown that SLC8A3 can be modulated by various drugs, including those that specifically target its activity on NMDA receptors. Furthermore, SLC8A3 has been shown to play a role in the regulation of pain-related ion channels, including the NMDA receptor, suggesting that its function in this process may be related to pain perception and neurotransmission.

In vivo studies have demonstrated that SLC8A3 is involved in the regulation of pain and inflammation. SLC8A3-deficient mice have been shown to exhibit increased pain sensitivity and inflammation, suggesting that SLC8A3 plays a role in the regulation of these processes. Furthermore, SLC8A3 has

Protein Name: Solute Carrier Family 8 Member A3

Functions: Mediates the electrogenic exchange of Ca(2+) against Na(+) ions across the cell membrane, and thereby contributes to the regulation of cytoplasmic Ca(2+) levels and Ca(2+)-dependent cellular processes. Contributes to cellular Ca(2+) homeostasis in excitable cells, both in muscle and in brain. In a first phase, voltage-gated channels mediate the rapid increase of cytoplasmic Ca(2+) levels due to release of Ca(2+) stores from the endoplasmic reticulum. SLC8A3 mediates the export of Ca(2+) from the cell during the next phase, so that cytoplasmic Ca(2+) levels rapidly return to baseline. Contributes to Ca(2+) transport during excitation-contraction coupling in muscle. In neurons, contributes to the rapid decrease of cytoplasmic Ca(2+) levels back to baseline after neuronal activation, and thereby contributes to modulate synaptic plasticity, learning and memory (By similarity). Required for normal oligodendrocyte differentiation and for normal myelination (PubMed:21959935). Mediates Ca(2+) efflux from mitochondria and contributes to mitochondrial Ca(2+) ion homeostasis (By similarity)

The "SLC8A3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC8A3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets